APA (7th ed.) Citation

Hao, Y., Xie, F., Zhou, Y., Li, C., Zhang, X., Shen, J., . . . Peng, W. (2024). Neoadjuvant therapy of sequential TACE, camrelizumab, and apatinib for single huge hepatocellular carcinoma (NEO-START): Study protocol for a randomized controlled trial. Trials, 25(1), 1. https://doi.org/10.1186/s13063-024-08340-1

Chicago Style (17th ed.) Citation

Hao, Yun, et al. "Neoadjuvant Therapy of Sequential TACE, Camrelizumab, and Apatinib for Single Huge Hepatocellular Carcinoma (NEO-START): Study Protocol for a Randomized Controlled Trial." Trials 25, no. 1 (2024): 1. https://doi.org/10.1186/s13063-024-08340-1.

MLA (9th ed.) Citation

Hao, Yun, et al. "Neoadjuvant Therapy of Sequential TACE, Camrelizumab, and Apatinib for Single Huge Hepatocellular Carcinoma (NEO-START): Study Protocol for a Randomized Controlled Trial." Trials, vol. 25, no. 1, 2024, p. 1, https://doi.org/10.1186/s13063-024-08340-1.